Literature DB >> 12428073

Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts.

Veit Gülberg1, Ingrid Liss, Manfred Bilzer, Tobias Waggershauser, Maximilian Reiser, Alexander L Gerbes.   

Abstract

BACKGROUND: We have recently shown that the transjugular intrahepatic portosystemic shunt (TIPS) is more effective than paracentesis in the treatment of cirrhotic patients with severe ascites and can prolong survival in selected patients. Although an improved quality of life (QOL) has been suggested in these patients after the TIPS procedure, so far there are no data available to substantiate this assumption. Therefore, the aim of this study was to determine the effect of TIPS on the QOL in cirrhotic patients with refractory or recidivant ascites.
METHODS: 21 cirrhotic patients who underwent TIPS for refractory or recidivant ascites were investigated. All patients were pretreated with repeated paracentesis for at least 1 year. Before the procedure and at 3 and 6 months during follow-up, the patients themselves rated QOL, fatigue and physical performance on a visual analogue scale (range 0-100). Furthermore, QOL was determined by the QOL index (range 0-10) according to Spitzer.
RESULTS: Patients' rating of the QOL on the visual analogue scale significantly increased from 35 +/- 25 (baseline) to 64 +/- 28 (3 months), and 66 +/- 24 (6 months; p = 0.02). Similarly, the QOL index significantly increased from 6.9 +/- 2.0 (baseline) to 8.3 +/- 2.1 (3 months), and 8.6 +/- 1.7 (6 months; p < 0.001). The increase of QOL was more pronounced in patients with complete response to TIPS.
CONCLUSIONS: We demonstrate that TIPS for refractory or recidivant ascites improves the QOL in patients with cirrhosis. Our data indicates that this improvement is dependent on the response to therapy. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2002        PMID: 12428073     DOI: 10.1159/000065593

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

1.  Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.

Authors:  Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Naotaka Shimozato; Kosuke Kaji; Hiroaki Takaya; Yukihisa Fujinaga; Yasuhiko Sawada; Shinya Sato; Soichiro Saikawa; Takuya Kubo; Takemi Akahane; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  Exp Ther Med       Date:  2020-11-10       Impact factor: 2.447

2.  Progress in treatment of massive ascites and hepatorenal syndrome.

Authors:  Alexander L Gerbes; Veit Gulberg
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

3.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

Review 4.  Palliative care for patients with end-stage liver disease.

Authors:  Anne M Larson
Journal:  Curr Gastroenterol Rep       Date:  2015-05

5.  Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease.

Authors:  Sundeep J Punamiya; Deepak N Amarapurkar
Journal:  Int J Hepatol       Date:  2011-07-02

6.  Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.

Authors:  Motoh Iwasa; Tomoaki Ishihara; Michio Kato; Ayako Isoai; Ryosuke Kobayashi; Naoko Torii; Noriko Soneda; Yoshiyuki Takei
Journal:  Intern Med       Date:  2019-07-10       Impact factor: 1.271

7.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.